Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest hit by US product delays

This article was originally published in Scrip

Executive Summary

Forest Laboratories has suffered setbacks to its pipeline after a meeting with the US FDA prompted it to postpone its NDA for the COPD treatment aclidinium bromide, which is being developed under a partnership with Almirall. On the same day, the company announced it was pushing back the US launch of its SNRI Savella (milnacipran HCl) for fibromyalgia while it seeks approval for a minor change.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel